NAS10028,385−3.46%S&P7,580−1.82%GOLD$3,899−3.29%BTC$77,885+0.58%VIX19.42+12.91%latest tape · as of 12:03 UTC
The Screen · Healthcare · Drug Manufacturers - General
Gilead Sciences
GILD · a US exchange · USD · Market cap $205.3B · 17,000 employees
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
FAIL · Does not pass the screen
170.68 USD
Price as of 30 Oct 2026Daily close, not a live quote
Screened 2026-10-30 · the tape above runs as of 12:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.50, read 2026-11-01
Ethical does not pass the values gate
Price170.68 USD
Fair value157.53
Ethical score10.0/100
RatingAVOID
Our investment reviews on this name
2026-10-18Read Markup157.37+8.5% to today ✓Accumulation gives way to Markup first Markup read since August
2026-10-11Read Accumulation150.93+13.1% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown150.93+13.1% to today Accumulation gives way to Markdown after a 5% rise in 4 weeks
2026-09-05Read Accumulation143.44+19.0% to today ✓Markup gives way to Accumulation after an 11% rise in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Gilead Sciences holds its Markup at $170.68. The statistical read favours the buyers, held for 6 days.
As held on the ledger · 2026-10-30
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 6 days
Price at the screen
$170.68
Valuation
N/A trailing · 16.71 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.33
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
42.25%
Below 33%
Interest-bearing debt is 42.2% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
5.04%
Below 33%
Cash held in interest-bearing accounts and securities is 5.0% of assets, under the one-third limit.
Pass
Receivables
21.14%
Below 49%
Money owed to the company is 21.1% of assets, under the 49% limit.
Pass
Revenue purity
1.19%
Below 5%
Only 1.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Gilead Sciences's business is in a permissible area, but its interest-bearing debt is about 42% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-31. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when GILD's ethical verdict changes
Today GILD does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads AVOID: it trades above our $157.53 fair value estimate, strong competitive moat, 10.20% revenue growth.
Fair value range in USD, drawn from the 2026-10-30 screen. The gold marker is the market price at the same screen. The price runs 7.7% above the base estimate.
Third-party analyst targets: 26 covering, consensus Buy. The average target sits −3% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-30 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Unethical Debt Woes for Gilead's Valuation
Imagine a pharmaceutical lab in the heart of the US, working on life-saving treatments, a beacon of hope for countless patients. That's Gilead Sciences, with a strong moat in its industry and a promising 10% revenue growth. But for all its medical prowess, the company is weighed down by a significant debt ratio that fails our ethical screen. This is why we're steering clear.
Gilead's market price of $143.44 sits comfortably under our fair value estimate of $154.88, suggesting an 8% margin of safety. The company boasts a strong moat and a consensus buy rating from 27 analysts, with a median target price of $160. Despite this, the profit margin is deeply in the red at -11%, and the Return on Equity (ROE) is -21%, painting a picture of financial distress.
Risks are glaringly obvious here, with the ethical failings around debt being a central concern. Coupled with the profit and ROE figures, it's clear that Gilead's financial health is compromised. While the valuation might look tempting, the underlying ethical and financial issues劝 us to stay on the sidelines. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GILD trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Markup$156.04-0.8%Entry 23
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (26 analysts) rates it buy, with a mean price target of $160. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$157.37+0.0%Entry 22
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (26 analysts) rates it buy, with a mean price target of $160. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markup$157.37+0.0%Entry 21
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (26 analysts) rates it buy, with a mean price target of $160. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markup$157.37+0.0%Entry 20
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (26 analysts) rates it buy, with a mean price target of $160. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup$157.37+0.0%Entry 19
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (26 analysts) rates it buy, with a mean price target of $160. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markup$157.37+0.0%Entry 18
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (26 analysts) rates it buy, with a mean price target of $160. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markup$157.37+0.0%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (26 analysts) rates it buy, with a mean price target of $160. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markup$157.37+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (26 analysts) rates it buy, with a mean price target of $160. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markup · changed$157.37+4.3%Entry 15
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (26 analysts) rates it buy, with a mean price target of $160.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (26 analysts) rates it buy, with a mean price target of $159.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
